Author:
Kibirige Davis,Andia-Biraro Irene,Kyazze Andrew Peter,Olum Ronald,Bongomin Felix,Nakavuma Rose Mwanje,Ssekamatte Phillip,Emoru Reagan,Nalubega Goretti,Chamba Nyasatu,Kilonzo Kajiru,Laizer Sweetness Naftal,Mrema Lucy Elauteri,Olomi Willyhelmina,Minja Lilian Tina,Ntinginya Nyanda Elias,Sabi Issa,Hill Philip C.,te Brake Lindsey,van Crevel Reinout,Sharples Katrina,Critchley Julia
Abstract
AbstractDiabetes mellitus (DM) increases the risk of developing tuberculosis infection (TBI). However, the evidence on the burden and phenotypic characteristics of TBI in African patients with DM is limited. This study aimed to determine the prevalence and characterisation of TBI in native African patients living with DM. We searched PubMed, EMBASE, and African Journals Online for original studies reporting information on the prevalence and characteristics of TBI in adult Africans with DM. A forest plot was used to describe the pooled prevalence estimate of TBI and the corresponding 95% confidence intervals (CI). Six studies conducted in four African countries involving 721 participants with DM were included in this systematic review. The pooled prevalence estimate of TBI was 40% (95% CI 20–60%, I2 = 98.52%, p < 0.001). Age ≥ 40 years and glycated haemoglobin levels independently predicted TBI positivity in patients with DM in three studies. Africans with DM have a high prevalence of TBI, especially those who are older or with poorly controlled diabetes. This justifies the need for studies to explore how to screen and manage TBI to avert the progression to active TB disease.
Funder
European and Developing Countries Clinical Trials Partnership (EDCTP) 2 program supported by the European Union
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. IDF. International Diabetes Federation Diabetes Atlas 10th Edition. https://diabetesatlas.org/regional-factsheets/ (accessed 16 March 2023) (2021).
2. WHO. World Health Organization. Global tuberculosis report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (accessed on 16 March 2023) (2022).
3. Simmons, J. D. et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat. Rev. Immunol. 18, 575–589. https://doi.org/10.1038/s41577-018-0025-3 (2018).
4. Trauer, J. M. et al. Risk of active tuberculosis in the five years following infection … 15%?. Chest 149, 516–525. https://doi.org/10.1016/j.chest.2015.11.017 (2016).
5. Getahun, H., Matteelli, A., Chaisson, R. E. & Raviglione, M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127–2135. https://doi.org/10.1056/NEJMra1405427 (2015).